Clinical trial NCT05989087: The Resting-state EEG Gamma Oscillations in Alzheimer's Disease
Official title: The Underestimated Utility of Resting-state Gamma Oscillations: Both Increase and Decrease of Gamma Discriminates Early-onset Alzheimer's Disease Patients From Healthy Individuals
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Alzheimer Disease, Early Onset
Keywords: Alzheimer's disease
Gamma activity
Resting-state EEG
Discriminative power
MRI
Lead sponsor: Dokuz Eylul University
Sponsor class: OTHER
First posted: 2023-08-14
Enrollment: 51
Sex: ALL
Maximum age (years): 65
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The present study included a retrospective investigation of EEG and MRI data. The total sample for the study consisted of 24 early-onset Alzheimer's disease patients and 24 healthy controls.

Brief summary: The literature suggests a strong association between amyloid accumulation and gamma alterations, emerging gamma activity as a biomarker candidate for Alzheimer's pathology. The present study aims to investigate resting-state gamma activity changes in Cerebrospinal fluid (CSF)-proven early-onset Alzheimer's disease (EOAD) patients with a holistic approach that employs structural and functional brain neuroimaging techniques, and neuropsychological aspects.

Detailed description: This cross-sectional study included 24 drug-naive CSF-proven EOAD patients and age-, sex, and education-matched healthy controls. All participants underwent a detailed neuropsychological evaluation, resting-state electroencephalography (EEG) recording, and Magnetic Resonance Imaging (MRI). Gamma power and coherence were measured in total gamma (30-48 Hz), gamma-1 (30-35 Hz), gamma-2 (35-40 Hz), and gamma-3 (40-48 Hz) frequency bands. Gray matter volumes were extracted for 54 regions of interest (ROIs) and compared between groups. Discriminant analysis was performed to determine the classification accuracy of gamma activity for EOAD. Finally, correlations between CSF, neuropsychological tests, EEG, and MRI measures were explored.

Eligibility criteria: Inclusion Criteria:

* For all participants: Age \< 65
* For EOAD patients: Meeting National Institute on Aging-Alzheimer's Association diagnostic criteria.
* For healthy controls: Mini-Mental State Examination (MMSE) \>25 Instrumental Activities of Daily Living Scale (IADL) = 8

Exclusion Criteria:

* For EOAD patients: MMSE \> 24 Geriatric depression scale (GDS) \> 14 Having treatment with antipsychotics and comorbidities that may affect cognitive abilities.
* For healthy controls: Having neurological and/or cognitive abnormalities Having a history of neurological, psychiatric, or systemic disorders, and alcohol/drug abuse. GDS \> 14
* For all participants: Having neurological (other than AD) or any other serious disease (cancer, systemic disease)

Primary outcomes:
measure: EEG
timeFrame: Day 2
Secondary outcomes:
measure: Correlation Analysis
timeFrame: 3 months
measure: Discriminant Analysis
timeFrame: 3 months
measure: MRI
timeFrame: Day 1
Other outcomes:
Locations:
city: İzmir
country: Turkey
facility: İzmir University of Economics
Study officials:
References: